GlassScriptPhysician profile
Michael Hanger
NPI 1215484753
$5,271.27
in general payments reported to CMS, 2019-2025
34 companies · $694 in 2025
The $694 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $843 · 2022: $881 · 2023: $1,389 · 2024: $1,465 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,002.95 | 2021-2025 | |
| Axsome Therapeutics, INC. | $572.49 | 2022-2025 | Auvelity |
| Novo Nordisk INC | $544.21 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $525.97 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $302.63 | 2023-2025 | |
| Glaxosmithkline, LLC. | $278.12 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $223.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $221.54 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.69 | 2021-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $200.57 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $159.67 | 2021-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $109.90 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.62 | 2023-2025 | Caplyta |
| Insightec,INC | $98.03 | 2023 | Exablate |
| Amarin Pharma, INC. | $91.45 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $88.84 | 2021-2024 | Unithroid |
| Daiichi Sankyo INC. | $78.45 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $68.14 | 2021 | |
| Supernus Pharmaceuticals, INC. | $57.10 | 2024 | Qelbree |
| Edwards Lifesciences Corporation | $35.83 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $33.66 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $27.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $26.71 | 2021 | |
| Sumitomo Pharma America, INC. | $25.05 | 2023 | Gemtesa |
| Agios Pharmaceuticals, INC. | $24.75 | 2023 | Pyrukynd |
| Corcept Therapeutics | $24.51 | 2025 | Korlym |
| Astellas Pharma US INC | $23.65 | 2024 | Veozah |
| Dexcom, INC. | $22.23 | 2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $19.21 | 2024 | (Ck6) Holter |
| Ultragenyx Pharmaceutical INC. | $18.79 | 2022 | |
| Watermark Medical, INC. | $14.81 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.50 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.36 | 2023 | Quviviq |
| Genentech USA, INC. | $10.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.